Response optimization of drug dosage: antiarrhythmic studies with tocainide
- PMID: 872495
- DOI: 10.1002/cpt197722142
Response optimization of drug dosage: antiarrhythmic studies with tocainide
Abstract
The benefits of using antiarrhythmic response to optimize dosage regimens of antiarrhythmic drugs in individual patients have been examined. Graded antiarrhythmic response and simultaneously measured plasma drug concentrations have been obtained in 15 patients receiving multiple oral doses of a new antiarrhythmic, tocainide. Plasma drug concentration-antiarrhythmic response data from each of 11 subjects responding to the drug have been fitted by a generalized concentration effect function which is valid over the entire range of response. With the use of experimentally determined pharmacokinetic parameters to define the dose-plasma concentration relationship and plasma drug concentration-response parameters estimated for individual patients, simulations were carried out to show the effect of various dosage regimens on antiarrhythmic response in individual patients. Such simulations provide a means of assessing antiarrhythmic effect in the range of clinical interest (80% to 100% of maximum effect), where the antiarrhythmic effect is a nonlinear function of dose, plasma drug concentration, or their logarithms. The simulations also demonstrate that for identical daily doses and dosing intervals patients show marked variability in antiarrhythmic response.
Similar articles
-
Reliability of antiarrhythmic drug plasma concentration monitoring.Clin Pharmacokinet. 1983 Jan-Feb;8(1):63-82. doi: 10.2165/00003088-198308010-00004. Clin Pharmacokinet. 1983. PMID: 6404580 Review.
-
Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide.Circulation. 1976 Dec;54(6):885-9. doi: 10.1161/01.cir.54.6.885. Circulation. 1976. PMID: 791536 Clinical Trial.
-
Antiarrhythmic effect of a new class 1 antiarrhythmic drug, AN-132, on ventricular arrhythmias in beagles.Cardiovasc Drugs Ther. 1989 Oct;3(5):683-9. doi: 10.1007/BF01857620. Cardiovasc Drugs Ther. 1989. PMID: 2488108
-
Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1217-22. doi: 10.1097/00005344-198611000-00018. J Cardiovasc Pharmacol. 1986. PMID: 2434749
-
Therapeutic drug monitoring of antiarrhythmic drugs.Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004. Clin Pharmacokinet. 2003. PMID: 12844326 Review.
Cited by
-
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002. Clin Pharmacokinet. 1981. PMID: 7032803 Review. No abstract available.
-
Efficacy and tolerance of tocainide during acute and long-term treatment of chronic ventricular arrhythmias.Eur J Clin Pharmacol. 1980 Oct;18(4):301-10. doi: 10.1007/BF00561386. Eur J Clin Pharmacol. 1980. PMID: 6777178 No abstract available.
-
Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man.Psychopharmacology (Berl). 1981;75(2):158-64. doi: 10.1007/BF00432179. Psychopharmacology (Berl). 1981. PMID: 6275440
-
Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.Clin Pharmacokinet. 1991 Feb;20(2):151-66. doi: 10.2165/00003088-199120020-00006. Clin Pharmacokinet. 1991. PMID: 2029806 Review.
-
Tocainide. A review of its pharmacological properties and therapeutic efficacy.Drugs. 1983 Aug;26(2):93-123. doi: 10.2165/00003495-198326020-00001. Drugs. 1983. PMID: 6411445 Review.